Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/EPRX/Net income

EUPRAXIA PHARMACEUTICALS INC. (EPRX) Net income 2022–2025

EUPRAXIA PHARMACEUTICALS INC. (EPRX) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.

-$38.6MFY2025 · since FY2022: -$18.5M → -$38.6M
22232425
Fiscal yearValueYoY
FY2025-$38.6M-51.3%
FY2024-$25.5M+9.6%
FY2023-$28.2M-52.6%
FY2022-$18.5M—

Source: SEC XBRL filings · For reference only · Not investment advice

More EPRX financial trends

EPRX RevenueEPRX Net marginEPRX Gross profitEPRX Gross marginEPRX Operating incomeEPRX Operating marginEPRX Operating cash flowEPRX Free cash flowEPRX Capital expendituresEPRX Return on equityEPRX Stock buybacksEPRX Dividends paidEPRX Total assetsEPRX Total liabilitiesEPRX Shareholders’ equityEPRX overview →